Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Type: Journal article
Title: Dose selection, pharmacokinetics, and pharmacodynamics of BRAF inhibitor dabrafenib (GSK2118436)
Author: Falchook, G.
Long, G.
Kurzrock, R.
Kim, K.
Arkenau, H.
Brown, M.
Hamid, O.
Infante, J.
Millward, M.
Pavlick, A.
Chin, M.
O'Day, S.
Blackman, S.
Curtis, C.
Lebowitz, P.
Ma, B.
Ouellet, D.
Kefford, R.
Citation: Clinical Cancer Research, 2014; 20(17):4449-4458
Publisher: American Association for Cancer Research
Issue Date: 2014
ISSN: 1557-3265
Statement of
Gerald S. Falchook, Georgina V. Long, Razelle Kurzrock, Kevin B. Kim, H.-Tobias Arkenau, Michael P. Brown, Omid Hamid, Jeffrey R. Infante, Michael Millward, Anna Pavlick, Melvin T. Chin, Steven J. O'Day, Samuel C. Blackman, C. Martin Curtis, Peter Lebowitz, Bo Ma, Daniele Ouellet, and Richard F. Kefford
Abstract: Abstract not available
Keywords: Humans; Melanoma; Oximes; Imidazoles; Proto-Oncogene Proteins B-raf; Protein Kinase Inhibitors; Positron-Emission Tomography; Treatment Outcome; Drug Administration Schedule; Dose-Response Relationship, Drug; Mutation; Adult; Aged; Aged, 80 and over; Middle Aged; Female; Male
Rights: © 2014 American Association for Cancer Research.
RMID: 0030030880
DOI: 10.1158/1078-0432.CCR-14-0887
Appears in Collections:Medicine publications

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.